Upon migration to lymph nodes, CD103+ DCs engage CD8+ T cells through MHC-I–peptide complexes and co-stimulatory molecules such as CD80/CD86, ultimately inducing tumor-specific cytotoxic responses (51). This evidence concerns the gene CD8A and neoplasm.